{'fraction_non_alphanumeric': 0.033967391304347824, 'fraction_numerical': 0.028532608695652172, 'mean_word_length': 5.522123893805309, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Successful prolonged use of recombinant human insulin‐like growth factor‐1 in a child with cystic fibrosis

Growth failure is a common and complicated process in children with cystic fibrosis (CF). Growth hormone, which is becoming a more commonly used agent in such patients, has demonstrated beneficial effects aside from increased growth velocity. Recently, insulin‐like growth factor‐1 has gained significant attention in the understanding of growth failure in children with CF. We report the successful prolonged use of recombinant human insulin‐like growth factor‐1 in an adolescent boy with CF, who demonstrated significant clinical benefits from the therapy. Pediatr. Pulmonol. 2011; 46:1137–1141. © 2011 Wiley Periodicals, Inc.